Search This Blog

Monday, February 3, 2014

GSK gains FDA Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag) for severe aplastic anaemia | 2014 | Press releases | Media | GlaxoSmithKline

GSK gains FDA Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag) for severe aplastic anaemia | 2014 | Press releases | Media | GlaxoSmithKline

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.